Can You Build Muscle on Semaglutide Without Losing It?

For laboratory and research use only. Not for human consumption.

The Muscle Loss Concern Is Real

Let’s not sugarcoat this: when you lose weight on semaglutide or other GLP-1 peptides, some of that weight loss comes from muscle. This isn’t unique to peptides — it happens with any method of weight loss. But the numbers are worth paying attention to.

In the STEP 1 trial, semaglutide produced an average weight loss of 17.32 kg. Of that, 6.92 kg was lean mass. That means roughly 40% of the weight lost was muscle and other lean tissue, not fat (PMC8089287).

A recent review in Obesity confirmed that lean soft tissue loss comprised 26% to 40% of total weight lost across multiple GLP-1 trials (PMC12536186).

This matters because muscle isn’t just about looking toned. Muscle is your metabolic engine — the more you have, the more calories you burn at rest. Losing too much muscle while losing weight can lower your metabolism, making weight regain more likely. It also affects strength, mobility, and long-term health.

Why This Happens

Muscle loss during weight loss isn’t caused by semaglutide directly attacking your muscles. It happens because of three related factors:

1. Caloric Deficit

Semaglutide works primarily by reducing appetite. You eat less. When your body needs more energy than you’re consuming, it breaks down both fat and muscle for fuel. This is basic biology — your body doesn’t exclusively burn fat during a deficit.

2. Reduced Protein Intake

When your appetite drops significantly, you eat less of everything — including protein. Protein is the building block your muscles need to maintain themselves. If protein intake falls too low, your body breaks down existing muscle to get the amino acids it needs for essential functions.

3. Reduced Physical Activity

Some people on GLP-1 peptides eat so little that they feel low on energy, especially early on. This can lead to less exercise and less physical activity overall. Muscles follow a “use it or lose it” rule — without regular stimulation, they atrophy.

A 2024 review framed this clearly: GLP-1 receptor agonists induce loss of lean mass in a way that’s consistent with caloric restriction in general, not as a unique pharmacological effect (PMC12322565).

How to Minimize Muscle Loss: The Three Pillars

The good news: muscle loss on semaglutide is not inevitable. Research shows you can significantly reduce or even prevent lean mass loss with the right strategies. A case series published in 2025 demonstrated that individuals can preserve or even increase lean tissue while on GLP-1 therapy, provided they follow specific lifestyle practices (PMC12536186).

Pillar 1: High Protein Intake

This is the single most important nutritional factor. Your muscles need protein to survive a caloric deficit. Without enough protein, your body will cannibalize existing muscle for amino acids.

The target: Aim for 1 gram of protein per pound of your goal body weight. If you currently weigh 200 lbs and your goal is 160 lbs, aim for 160 grams of protein daily.

This is harder than it sounds when your appetite is suppressed. Practical tips:

• Prioritize protein at every meal. Eat your protein source first, before filling up on other foods.
• Use protein shakes. When you can’t eat enough solid food, liquid protein is easier to get down.
• Track your intake. Even roughly. Most people dramatically overestimate how much protein they eat.
• Choose high-protein, low-volume foods. Greek yogurt, eggs, chicken breast, and fish pack a lot of protein without taking up much stomach space.

Pillar 2: Resistance Training

This is the single most important activity factor. Lifting weights sends your body a clear signal: “I need this muscle. Don’t break it down.”

A 2024 review on strategies for minimizing muscle loss during incretin-mimetic therapy specifically highlighted that resistance training, rather than aerobic exercise, is what prevents lean body mass loss during weight reduction (PMC11611443).

The successful case series mentioned above involved participants who exercised 4 to 7 days per week, including resistance training 3 to 5 days per week, with protein intakes of 0.7 to 1.7 g/kg per day.

A practical plan for people on GLP-1 peptides:

Day	Focus	Examples
Monday	Upper body push	Bench press, overhead press, tricep work
Tuesday	Lower body	Squats, leg press, lunges, calf raises
Wednesday	Active recovery	Walking, stretching, light cardio
Thursday	Upper body pull	Rows, pull-ups/lat pulldowns, bicep work
Friday	Lower body + core	Deadlifts, hip thrusts, planks, leg curls
Saturday	Full body or weak points	Compound lifts, areas that need extra work
Sunday	Rest	Full rest or gentle walking

The key principles: lift heavy enough to challenge your muscles (not just going through the motions), focus on compound movements that work multiple muscle groups, and be consistent. Three sessions per week is the minimum for meaningful muscle preservation.

Pillar 3: Adequate Total Calories

This sounds counterintuitive — you’re trying to lose weight, so shouldn’t you eat less? Yes, but not too much less.

A moderate caloric deficit (500-750 calories below maintenance) preserves more muscle than an extreme deficit (1,000+ calories below maintenance). Semaglutide can suppress appetite so effectively that some people end up eating far too little — sometimes under 1,000 calories per day. At that level, muscle loss accelerates dramatically regardless of protein intake.

The goal: eat enough to fuel your training and protein needs, while still being in a reasonable deficit. Slower weight loss preserves more muscle.

Tirzepatide May Preserve More Muscle Than Semaglutide

Here’s an interesting finding: in the SURMOUNT-1 body composition substudy, participants on tirzepatide lost about 75% fat and 25% lean mass. That’s a much more favorable ratio than semaglutide’s roughly 60% fat / 40% lean mass split (PMC11965027).

The reason may be tirzepatide’s dual mechanism. It activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptors are found on fat tissue, and their activation appears to specifically target fat mobilization. This could explain why tirzepatide produces weight loss that’s more concentrated in fat tissue compared to semaglutide, which only hits GLP-1 receptors.

Direct head-to-head body composition comparisons are still limited, so this remains a hypothesis supported by indirect evidence rather than a definitive conclusion.

Retatrutide and Body Composition

Retatrutide adds a third receptor to the equation — the glucagon receptor. Glucagon promotes fat breakdown (lipolysis) and fat oxidation in the liver. In the phase 2 trial, retatrutide produced total fat mass reductions of up to 26.1% — significantly more than what’s typically seen with semaglutide alone (PMC12026077).

The glucagon receptor component is particularly interesting for body composition because glucagon’s primary metabolic role is mobilizing stored fat for energy. In theory, this means a greater proportion of weight loss may come from fat rather than muscle. A body composition substudy confirmed that retatrutide significantly improved total body fat mass reduction compared to both placebo and dulaglutide.

Phase 3 trials (the TRIUMPH program) are currently underway and will provide more definitive data on retatrutide’s body composition effects.

Growth Hormone Peptides as a Complement

Some researchers combine GLP-1 peptides with growth hormone secretagogues specifically to protect lean mass during weight loss.

Sermorelin stimulates your body’s natural growth hormone production, which plays a direct role in maintaining muscle mass and promoting fat metabolism. Studies have shown that GH secretagogue treatment can increase serum IGF-1 levels — a key marker of growth hormone activity — and produce fat loss with lean mass preservation (PMC5675260).

The logic of combining a GLP-1 peptide (for fat loss and appetite control) with a GH peptide (for muscle preservation) is straightforward: you address the weight loss and the muscle protection simultaneously, using two compounds that work through completely separate pathways.

A 2020 review specifically explored the role of GH secretagogues in body composition management and found that they can produce comparable fat loss and lean mass gains to direct GH therapy, but with a more natural pattern of GH release (PMC7108996).

What the Research Says About Exercise + GLP-1 Peptides

A 2025 perspective in Frontiers in Endocrinology on GLP-1 agonists and exercise concluded that combining GLP-1 therapy with structured exercise — particularly resistance training — represents the future of evidence-based lifestyle prioritization for patients using these medications (PMC12683586).

The evidence is clear and consistent: resistance training is not optional when using GLP-1 peptides for weight loss. It is essential for preserving the muscle that makes weight loss sustainable.

The Bottom Line

Yes, you can preserve muscle on semaglutide — but it takes deliberate effort. The three pillars are non-negotiable: high protein intake, regular resistance training, and a moderate (not extreme) caloric deficit. Tirzepatide and retatrutide may offer better body composition outcomes than semaglutide alone, and adding a GH peptide like sermorelin could further support lean mass preservation.

The worst approach is to take semaglutide, eat very little, skip the gym, and hope for the best. That’s how you lose 40% muscle. The best approach is to treat semaglutide as one tool in a comprehensive strategy that includes training, nutrition, and possibly complementary peptides.

Written by NorthPeptide Research Team

Summary of Key Research References

Topic	Reference	PMC ID
STEP 1 body composition analysis	Impact of Semaglutide on Body Composition: Exploratory Analysis of STEP 1 (2021)	PMC8089287
Lean tissue preservation on GLP-1/GIP agonists	Preservation of lean soft tissue during weight loss: A case series (2025)	PMC12536186
GLP-1 agonists and lean mass loss	GLP-1 receptor agonists induce loss of lean mass: so does caloric restriction (2025)	PMC12322565
Strategies for minimizing muscle loss	Strategies for minimizing muscle loss during incretin-mimetic drugs (2024)	PMC11611443
SURMOUNT-1 body composition substudy	Body composition changes during tirzepatide in SURMOUNT-1 (2025)	PMC11965027
Retatrutide efficacy and fat mass reduction	Retatrutide for obesity: systematic review and meta-analysis (2025)	PMC12026077
GH secretagogues and body composition	Beyond the androgen receptor: GH secretagogues in body composition (2020)	PMC7108996
GH secretagogue treatment raises IGF-1	Growth Hormone Secretagogue Treatment Raises Serum IGF-1 (2017)	PMC5675260
GLP-1 agonists and exercise	GLP-1 agonists and exercise: the future of lifestyle prioritization (2025)	PMC12683586
Muscle preservation strategies review	Saving muscle while losing weight: A vital strategy on GLP-1 drugs (2025)	PMC12444289

For laboratory and research use only. Not for human consumption.